This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
- Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer
- Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma
- Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer
- Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review
- Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 Cases
- Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- Bone metastases from differentiated thyroid carcinoma
- Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome
- Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
- Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management
- Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review
- The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma